Quality & Standards
With our vision to significantly improve the lives of patients, Converge’s strong product pipeline on generic products encompasses all major therapeutic areas and dosage forms while focusing on quality, affordability and patient needs around the globe.
The strategy to invest in R&D to develop high-value opportunities in generics is the potential for our future growth.
Our research on T cell-dependent immune responses provides a method for inhibiting at least one T cell activity, comprising the step of contacting a T cell with an agent that inhibits ATP-mediated T cell activation. T cell activity is selected from the group consisting of activation, proliferation, differentiation, survival, cytolytic activity and cytokine production.